whoops, posted this in general by mistake...
Stimuvax failed to reach its primary endpoint.
http://www.reuters.com/article/2012/12/19/us-merck-stimuvax-idUSBRE8BI0CA20121219
Unfortunately for Prima, CVac shares the same MUC-1 target.
While it doesn't suggest that CVac could also fail, as the technologies of the two therapies are quite different, it certainly won't build confidence.
Might be a good idea for management to put any fears to rest before they rise.
bad news for onty - stimuvax fails p3 trial
-
- There are more pages in this discussion • 15 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
30.0¢ |
Change
0.010(3.45%) |
Mkt cap ! $435.7M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.5¢ | 28.8¢ | $574.2K | 1.921M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 461775 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.5¢ | 100000 | 1 |
View Market Depth
| Last trade - 16.10pm 07/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |